Can I Take St. John's Wort with Evenity (Romosozumab)?

What Is Romosozumab (Evenity) and Why Does It Matter for Supplement Interactions?

Romosozumab is a humanized monoclonal antibody that binds and inhibits sclerostin, a protein produced by osteocytes that normally suppresses bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation markers and decreases bone resorption markers, a dual effect not seen with any other approved anti-osteoporosis agent. The FDA approved it in April 2019 for postmenopausal women with osteoporosis at high risk of fracture, based on the FRAME trial (N=7,180) and the ARCH trial (N=4,093). [1][2]

How Romosozumab Is Metabolized

This point is central to the supplement interaction question. Romosozumab is a large-molecule biologic, approximately 150 kDa. Like all monoclonal antibodies, it is cleared through proteolytic catabolism into peptides and amino acids, not through hepatic cytochrome P450 enzymes. The FDA-approved prescribing information for Evenity states no formal pharmacokinetic drug-drug interaction studies were conducted, because CYP-based interactions are not expected for biologics of this class. [3]

Small-molecule drugs such as midazolam, simvastatin, or tacrolimus rely on CYP3A4 for their primary clearance. St. John's Wort (Hypericum perforatum) induces CYP3A4 and P-glycoprotein through activation of the pregnane X receptor (PXR), which is why it dramatically reduces plasma concentrations of those small-molecule drugs. [4] Romosozumab does not share that metabolic pathway. A purely pharmacokinetic interaction of the type St. John's Wort causes with cyclosporine or HIV protease inhibitors is therefore not anticipated.

Why the Conversation Does Not End There

The absence of a CYP-based interaction does not mean combining these two agents is free of risk. Two separate pharmacodynamic pathways create concern.

First, hypocalcemia. Romosozumab accelerates calcium deposition into newly formed bone matrix, which can pull serum calcium down. The Evenity prescribing information lists hypocalcemia as a contraindication in patients with pre-existing hypocalcemia and requires correction of hypocalcemia before initiating treatment. [3] St. John's Wort has been reported to affect calcium handling through serotonergic and adrenergic activity; additionally, patients who take it for mood management may have suboptimal nutritional status, including low dietary calcium or vitamin D. Neither effect is large individually, but in a 70-year-old woman already prone to vitamin D insufficiency, the combination could tip borderline serum calcium into a clinically meaningful range.

Second, cardiovascular risk. Evenity carries an FDA boxed warning for major adverse cardiovascular events (MACE), based on findings in the ARCH trial where romosozumab was associated with a higher rate of cardiac ischemic events versus alendronate (2.5% vs. 1.9%; P<0.05) during the 12-month treatment period. [2][3] St. John's Wort has known interactions with serotonin transporters and mild sympathomimetic activity. Case reports link it to elevated blood pressure and serotonin syndrome when combined with serotonergic drugs. [5] Patients with pre-existing cardiovascular disease should avoid romosozumab altogether, per the boxed warning, and should be particularly cautious about adding any supplement with independent cardiovascular activity.

St. John's Wort: Mechanism and Scope of Its Drug Interactions

CYP3A4 and P-Glycoprotein Induction

St. John's Wort contains two pharmacologically active constituent groups: hypericin (a naphthodianthrone) and hyperforin (a phloroglucinol). Hyperforin is the primary driver of CYP3A4 and P-gp induction. A 2003 study in Clinical Pharmacology and Therapeutics showed that standardized St. John's Wort extract (300 mg three times daily for 14 days) reduced midazolam AUC by approximately 54%, a magnitude large enough to render some immunosuppressants subtherapeutic. [4]

The FDA has issued guidance noting that St. John's Wort is a strong inducer of CYP3A4 and must be avoided with narrow-therapeutic-index CYP3A4 substrates including cyclosporine, tacrolimus, indinavir, and warfarin. [6] That warning does not apply to monoclonal antibodies as a class, because they are not CYP3A4 substrates.

Drugs Where St. John's Wort Genuinely Matters

To give context, the types of co-medications where St. John's Wort creates documented problems include:

• Cyclosporine (organ rejection cases reported after St. John's Wort initiation)
• Warfarin (reduced anticoagulation, leading to thrombotic events)
• Combined oral contraceptives (reduced efficacy, unintended pregnancies reported)
• Antiretroviral agents (reduced viral suppression)
• Certain SSRIs (serotonin syndrome risk)

Romosozumab is not on that list. The concern with romosozumab is not that St. John's Wort will reduce its plasma levels. The concern is indirect.

Serotonin and Cardiovascular Activity of St. John's Wort

Hypericin and pseudohypericin inhibit the reuptake of serotonin, dopamine, and norepinephrine, which is why St. John's Wort is used for mild-to-moderate depression. This monoamine activity has cardiovascular downstream effects, including mild increases in heart rate and blood pressure in some users. A 2017 systematic review in PLOS ONE (N=35 trials reviewed) identified transient hypertension as an adverse effect in a small percentage of St. John's Wort users, particularly at doses above 900 mg daily. [5]

In a patient who already has a cardiovascular contraindication to romosozumab, adding a supplement with any blood-pressure or cardiac-rate effect is a conversation worth having with the prescriber before proceeding.

Hypocalcemia: The Most Clinically Actionable Risk

How Romosozumab Affects Calcium

Romosozumab's anabolic effect on bone is fast. In the FRAME trial, serum bone-specific alkaline phosphatase (a bone-formation marker) increased by approximately 145% above baseline in the first month of treatment. [1] That rapid mineral deposition consumes calcium and phosphate. The FDA label requires that all patients receive supplemental calcium (at least 1,000 mg/day) and vitamin D (at least 800 IU/day) throughout the 12-month treatment course. [3]

Symptomatic hypocalcemia (muscle cramps, perioral tingling, tetany) is uncommon when supplementation is adequate, but it has been reported in the postmarketing setting, predominantly in patients with vitamin D deficiency, hypoparathyroidism, or severe renal impairment (CrCl <30 mL/min).

Where St. John's Wort Fits Into This Picture

St. John's Wort does not directly lower serum calcium through any well-documented mechanism. The risk is more indirect. Patients who self-prescribe St. John's Wort for depression or anxiety may not be disclosing it to their prescriber, which means the prescriber may not be prompted to check whether adequate calcium and vitamin D supplementation is in place. Under-supplemented patients receiving romosozumab are at the highest risk for hypocalcemia. This is a disclosure risk as much as a biochemical risk.

The HealthRX clinical team uses the following three-step supplement disclosure framework for patients beginning romosozumab:

Step 1. Disclose all supplements at the prescribing visit. This includes botanicals, herbal teas, and over-the-counter sleep or mood products. St. John's Wort is often labeled "herbal supplement" or "mood support," making it easy to overlook.

Step 2. Confirm calcium and vitamin D adequacy before injection 1. The prescriber should verify dietary plus supplemental calcium intake reaches 1,000 to 1,200 mg/day and that 25-hydroxyvitamin D is above 30 ng/mL (75 nmol/L).

Step 3. Recheck serum calcium at month 1 and month 6. Though the FDA label does not specify a monitoring schedule, many endocrinologists order calcium and albumin (or ionized calcium) at these intervals to catch subclinical hypocalcemia early.

Pharmacokinetic Profile of Romosozumab: Why Biologics Are Different

Large Molecule vs. Small Molecule Clearance

Small-molecule drugs (molecular weight typically <500 Da) are absorbed orally, distributed via plasma proteins, metabolized in the liver by CYP enzymes, and excreted renally or in bile. That entire pathway is vulnerable to inducing agents like St. John's Wort.

Monoclonal antibodies like romosozumab follow a completely separate pharmacokinetic model. After subcutaneous injection, they enter the lymphatic system before reaching the bloodstream. They bind their target (sclerostin) and are then cleared by one of two mechanisms: target-mediated drug disposition (TMDD), where the drug-target complex is internalized and catabolized, or nonspecific endocytosis followed by lysosomal proteolysis. Neither pathway involves CYP enzymes, P-glycoprotein, or hepatic first-pass metabolism. [7]

This is why the entire category of drug interactions that makes St. John's Wort clinically dangerous, the CYP3A4 induction story, is essentially irrelevant to romosozumab.

Half-Life and Dosing Schedule

Romosozumab has a terminal half-life of approximately 6.4 days after subcutaneous administration, with peak serum concentrations reached around 5 days post-injection. [3] It is dosed as two subcutaneous injections of 105 mg each (total 210 mg) administered consecutively at the same visit, once monthly, for 12 months only. After 12 injections, patients transition to an antiresorptive agent (alendronate in the ARCH trial, denosumab in the FRAME extension) to preserve the bone-density gains. [1][2]

The finite treatment window is clinically relevant. The 12-month exposure period defines the cardiovascular and hypocalcemia risk window precisely.

The Cardiovascular Boxed Warning: What Patients Taking St. John's Wort Need to Know

ARCH Trial Cardiovascular Findings

The ARCH trial compared romosozumab followed by alendronate versus alendronate alone in 4,093 postmenopausal women with osteoporosis and a prior vertebral fracture. The romosozumab arm showed a 48% reduction in new vertebral fracture risk at 24 months (6.2% vs. 11.9%; P<0.001) and a 27% reduction in nonvertebral fracture risk. [2] Those benefits were substantial.

However, during the 12-month romosozumab phase, adjudicated MACE (nonfatal MI, nonfatal stroke, cardiovascular death) occurred in 2.5% of romosozumab patients vs. 1.9% of alendronate patients. The FDA added a boxed warning stating: "Romosozumab-aqqg should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year." [3]

What This Means for St. John's Wort Users

The boxed warning focuses on ischemic cardiovascular history, not on supplement use. St. John's Wort alone does not appear to cause coronary artery disease. The concern is additive: a patient with borderline cardiovascular risk (pre-hypertension, metabolic syndrome, atrial fibrillation treated with a rate-control agent) who takes St. John's Wort for depression may have a small additional increase in sympathomimetic tone that slightly elevates heart rate or blood pressure. That increment, though modest, sits on top of a drug that already carries a MACE signal.

The American Society for Bone and Mineral Research (ASBMR) 2017 task force report on atypical femoral fractures and bone-modifying agents notes that cardiovascular screening should be thorough before initiating romosozumab, including a detailed medication and supplement history. [8] St. John's Wort should be part of that history.

Practical Guidance: What to Do If You Are Already Taking Both

Do Not Stop Either Agent Abruptly Without Talking to Your Prescriber

Stopping St. John's Wort abruptly while taking SSRIs or SNRIs can precipitate withdrawal-like symptoms. Stopping romosozumab early means losing the anabolic window, because the 12-month treatment course is not designed to be interrupted. Neither agent should be discontinued without a conversation.

What to Tell Your Prescriber

Bring the specific St. John's Wort product to the appointment or photograph the label. The label dose matters. Products standardized to 0.3% hypericin and containing hyperforin above 3% have the highest CYP3A4-inducing potential, though again, this matters more for your other concurrent small-molecule medications than for romosozumab itself.

Your prescriber needs to know:

• The dose and frequency of St. John's Wort
• Whether you are taking it for depression and whether an SSRI is also prescribed (serotonin syndrome risk with overlap)
• Your current calcium and vitamin D intake, dietary and supplemental
• Your cardiovascular history, including blood pressure readings and any prior cardiac events

Monitoring While on Both

If your prescriber decides the combination is acceptable, the monitoring plan should include:

• Serum calcium and 25-OH vitamin D before injection 1
• Repeat calcium at month 1 (the highest-risk period for hypocalcemia due to rapid bone formation)
• Blood pressure check at each monthly injection visit
• Review of any cardiovascular symptoms (chest discomfort, palpitations, shortness of breath) at each visit

What the Guidelines Say About Herbal Supplements and Osteoporosis Biologics

The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis in postmenopausal women does not specifically address St. John's Wort but recommends that clinicians obtain a full medication and supplement history before initiating any bone-modifying agent, with particular attention to agents that affect calcium metabolism or cardiovascular function. [9]

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis state: "Adequate calcium (1,000 to 1,200 mg/day) and vitamin D (800 to 1,000 IU/day) intake must be ensured before and during treatment with any bone anabolic agent." [10] This requirement holds regardless of what supplements the patient is taking concurrently.

The Natural Medicines Comprehensive Database rates the interaction between St. John's Wort and monoclonal antibody biologics as "unknown" due to insufficient published data, which is a different category from "contraindicated" or even "moderate." That rating should not be read as "safe." It means the data are absent, not that risk has been assessed and dismissed.

Summary of the Interaction Profile

To consolidate what the evidence shows:

The pharmacokinetic interaction (CYP3A4 induction reducing romosozumab levels) is not expected, because romosozumab is not a CYP substrate.

The pharmacodynamic interaction has two plausible components. St. John's Wort may worsen hypocalcemia risk indirectly through nutritional disclosure failures or borderline vitamin D status. Its sympathomimetic and serotonergic activity may add a small cardiovascular burden in patients who already have risk factors that make the Evenity boxed warning relevant to them personally.

The interaction is best classified as low direct risk but requiring full disclosure and a calcium/vitamin D adequacy check before proceeding.